AVE Science & Technology Co

AVE Science & Technology Co FCF Growth

The Year-over-Year Free Cash Flow Growth of AVE Science & Technology Co (688067.SS) as of Nov 16, 2026 is 105.39 %. In the previous year, Year-over-Year Free Cash Flow Growth was 2.35 % — a change of 4,387.88% (higher).

FCF Growth

105.39 %

YoY

4,387.88%

Last updated:

Year-over-Year Free Cash Flow Growth of AVE Science & Technology Co is 2025 105.39 % . Year-over-Year Free Cash Flow Growth of AVE Science & Technology Co was 2024 2.35 % . It decreases by 4,387.88% higher compared to the previous year.

The AVE Science & Technology Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
198.69 CNY
Jan 1, 2019
63.58 CNY
Jan 1, 2020
-6.59 CNY
Jan 1, 2021
-24.08 CNY
Jan 1, 2022
-68.00 CNY
Jan 1, 2023
113.60 CNY
Jan 1, 2024
2.35 CNY
Jan 1, 2025
105.39 CNY
The AVE Science & Technology Co FCF Growth history
YEARFCF GrowthYoY
105.39 %+4,387.88%
2.35 %-97.93%
113.60 %-267.07%
-68.00 %+182.40%
-24.08 %+265.19%
-6.59 %-110.37%
63.58 %-68.00%
198.69 %-154.16%
-366.85 %-348.84%
147.42 %+19.78%
123.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Year-over-Year Free Cash Flow Growth of AVE Science & Technology Co is 105.39 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's AVE Science & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co